[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351778-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351778-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-diagnostic-randomized-controlled-trial-to-validate-novel-dried-blood-spot-dbs-based-technology-for-prognosis-and-screening-of-leukemia-transcripts-study-protocol","A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts - study protocol","","Leukemia presents major diagnostic access challenges for Indian children and adults because current molecular diagnostics and prognostic tests are concentrated in fewer than 20 centers nationwide, leading to delayed diagnosis, weaker risk stratification, higher economic burden, and increased mortality. This multicenter randomized double-blind diagnostic trial evaluates a novel dried blood spot (DBS)-based technology for leukemia transcript determination. Newly diagnosed acute leukemia patients (n=300: 200 ALL, 100 AML) will be randomized to DBS testing versus conventional testing. Primary outcomes assess sensitivity, specificity, and positive predictive value, with secondary outcomes including survival, event-free survival, and relapse over one year.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-diagnostic-randomized-controlled-trial-to-validate-novel-dried-blood-spot-dbs-based-technology-for-prognosis-and-screening-of-leukemia-transcripts-study-protocol/351778/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-diagnostic-randomized-controlled-trial-to-validate-novel-dried-blood-spot-dbs-based-technology-for-prognosis-and-screening-of-leukemia-transcripts-study-protocol/351778.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is a new DBS-based diagnostic technology needed for leukemia?","Question",{"text":63,"@type":64},"Current molecular and prognostic leukemia diagnostics are not widely available across India, especially in remote and tier-two settings. Limited access contributes to delayed diagnosis, poorer risk stratification, increased costs, and higher mortality.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the trial designed and who will be enrolled?",{"text":68,"@type":64},"The study is a multicenter randomized double-blind diagnostic interventional trial across five sites in India. Newly diagnosed acute leukemia patients (n=300; 200 ALL and 100 AML) will be randomized to an interventional DBS-based arm or a comparator conventional testing arm.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes will be used to validate the DBS-based method?",{"text":72,"@type":64},"The primary outcome compares sensitivity, specificity, and positive predictive value of the DBS-based method versus conventional diagnostic methods. Secondary outcomes include overall survival, event-free survival, and relapse rates over one year of follow-up.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351778,1790604127,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Sharma et al. Trials (2026) 27:409  \n[https://doi.org/10.1186/s13063-026-09571-0](https://doi.org/10.1186/s13063-026-09571-0)  \nTrials  \n STUDY PROTOCOL Open Access  \nA diagnostic randomized controlled trial  \nto validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol  \nSaurabh Sharma1†, Sandeep Kumar Swain2†, Bhavika Rishi2, Manpreet Kaur2, Gratial Theres Joseph2, Noreen Grace George2, Neetu Kushwaha2, Himanshu Dhanda2, Rajkamal2, Surbhi2, Sumita Chaudhry3, Debasish Sahoo4, Aditi Jain3, Amitabh Singh3, Fouzia Siraj5 and Aroonima Misra2*  \nAbstract  \nBackground Leukemia is the most common subtype of cancer in Indian children and ranks among the top ten cancers in the adult population according to ICMR cancer registry 2022 (National Cancer Registry Programme, Cancer incidence and mortality in India 2022, 2022) . Current leukemia diagnostics rely on sophisticated molecular tests that are not available at all healthcare centers, particularly in remote and tier-two cities. Access to specialized molecular diagnostics and prognostic tests is limited to fewer than 20 centers across India, serving a population of approximately 1.3 billion people (National Cancer Registry Programme, Cancer incidence and mortality in India 2022, 2022) . This restricted accessibility results in delayed diagnosis, suboptimal risk stratification, increased economic burden, and higher mortality rates compared to high-income countries.  \nMethods This is a multicenter, randomized, double-blind diagnostic interventional trial designed to validate a novel dried blood spot (DBS) based technology for leukemia transcript determination. The study will be conducted across five sites in India. Newly diagnosed acute leukemia patients (n= 300; 200 ALL and 100 AML) will be randomized into two arms: interventional arm (DBS-based testing) and comparator arm (conventional testing) . The primary outcome is the sensitivity, specificity, and positive predictive value of the DBS-based method compared to conventional diagnostic methods. Secondary outcomes include overall survival, event-free survival, and relapse rates over one year of follow-up.  \nDiscussion This study addresses a critical gap in leukemia diagnostic accessibility in low-and middle-income countries. The novel DBS-based technology has the potential to withstand tropical temperature and humidity conditions for 24–48 h, making it suitable for transport from remote areas. Preliminary work has shown 100% specificity and 99% sensitivity compared to standard reference methods (PLoS One 13(1):e0191421, 2019) . If validated, this technology could significantly improve leukemia outcomes through earlier diagnosis, better risk stratification, and reduced abandonment rates.  \n†Saurabh Sharma and Sandeep Kumar Swain are joint first authors.  \n*Correspondence: Aroonima Misra[dr.aroo.2402@gmail.com](dr.aroo.2402@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this lice","cbCain3JDlZ8b06y","https://ap.wps.com/l/cbCain3JDlZ8b06y","pdf",1253648,18,"English","# Abstract\n## Background\n## Methods\n## Discussion\n# Administrative information\n## Trial registration\n## Protocol version\n## Funding\n## Keywords","[{\"question\":\"Why is a new DBS-based diagnostic technology needed for leukemia?\",\"answer\":\"Current molecular and prognostic leukemia diagnostics are not widely available across India, especially in remote and tier-two settings. Limited access contributes to delayed diagnosis, poorer risk stratification, increased costs, and higher mortality.\"},{\"question\":\"How is the trial designed and who will be enrolled?\",\"answer\":\"The study is a multicenter randomized double-blind diagnostic interventional trial across five sites in India. Newly diagnosed acute leukemia patients (n=300; 200 ALL and 100 AML) will be randomized to an interventional DBS-based arm or a comparator conventional testing arm.\"},{\"question\":\"What outcomes will be used to validate the DBS-based method?\",\"answer\":\"The primary outcome compares sensitivity, specificity, and positive predictive value of the DBS-based method versus conventional diagnostic methods. Secondary outcomes include overall survival, event-free survival, and relapse rates over one year of follow-up.\"}]","A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts - study protocol | PDF",1790095857,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/354ab8a98fafc36ee7103123993c4996.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0401df3812ea300e855f66366739b10d.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9ea3233663626e7aeeea3b95ffb4032.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c88677c0e7953873ecf417d6d1d048b.webp",980,1301]